2. Senseonics implantable CGM
Senseonics (NYSE:SENS) is one of the leaders in the continuous glucose monitoring space, with its implantable Eversense System that launched last month.
The Eversense System is a long-term, implantable CGM sensor that features a transmitter that sends discreet vibrations to alert users of low and high glucose levels. The system with the CGM mobile app can dose insulin based on system readings without the need for a confirmatory blood glucose finger stick measurement.
The device features a fluorescence-based sensor, a smart transmitter worn over the sensor for data communication and a mobile app to display glucose values, trends and alerts. The sensor is inserted subcutaneously in the upper arm by a physician and requires two calibrations per day.
Eversense CGM is one of many CGM systems out there, including one from Pops! Diabetes Care, which had its commercial launch in March 2019.
Abbott has already seen success with its FreeStyle Libre glucose monitoring system; the company last year touted real-world data showing reduced prolonged hypoglycemia and better glucose control among system users.
